New York, NY, April 28, 2017 - Reversing career-ending injuries like chronic tendinosis, a common medical condition caused by a cycle of incomplete healing and re-injury that leads to a painful degenerative state, is the focus for Replicel Life Sciences Inc., a clinical stage regenerative medicine company. Tendinosis is often caused by sports-related injuries, occupational overuse, aging and poor general health. Chronic Achilles tendinosis can affect both physically active and inactive individuals, accounting for 30 to 50% of all sports injuries and 50% of occupation-related disorders in the United States.
The company’s cell therapies are designed to treat chronic tendinosis, damaged or aged skin, and pattern baldness. The company is also developing a propriety, next-generation injection device (RCI) for optimal clinical delivery. Each condition is related to a deficit of a specific cell type which we believe is critical to the restoration of normal function.
The injected cells promote the healing process by producing proteins that are necessary for restoring tissue’s structural integrity as well as type 1 collagen fibers which orientate themselves along the direction of the stretch of the tendon. “The anticipated long-term outcome is the return of normal tendon structure, improved function and zero pain,” according to company CEO Lee Buckler.
Dr. Ross Davidson, an orthopedic surgeon, former clinical professor at the Department of Orthopaedics at the University of British Columbia, and past head physician and orthopaedic consultant for the Vancouver Canucks (of the National Hockey League (NHL)), adds: “This study shows exciting clinical improvements in patients with clinically diagnosed chronic Achilles tendinosis who were unresponsive to standard treatments, and who had suffered for many months (in some cases, years) with frequent pain and loss of function. Not only did the study show several clinically important improvements in pain and function scores, but several ultrasound measures clearly demonstrate a marked improvement in tendon structure; something rarely seen in patients with this condition.”
RepliCel, a regenerative medicine company based in Vancouver, Canada, is focused on developing autologous cell therapies that address diseases caused by a deficit of healthy cells required for normal healing and function.
RepliCel has also successfully pioneered regenerative cell therapy as a non-invasive cure for hair loss; partnering the Japanese giant Shiseido.
Lee Buckler has been an executive in the cell therapy sector since 2000, beginning with Malachite Management in the Stem Cell Technologies group of companies. Most recently he was the Managing Director of Cell Therapy Group, a firm he formed in 2008 where he did business development consulting for companies and organizations in, or interested in, the cell therapy sector. His work included deal-targeting, transactions, market intelligence, competitive analyses, strategic assessments, and market profile planning for companies ranging from top-tier multinationals to start-ups.
Mr. Buckler has a Bachelor’s Degree in Education and a Law Degree. Buckler served six years as the Executive Director of the International Society for Cellular Therapy and Director of Business Development for Progenitor Cell Therapy. He is on the editorial advisory boards of the journal Regenerative Medicine and the BioProcess International magazine, as well as the co-chair of the Alliance for Regenerative Medicine’s Communications and Education Committee. He co-founded Cell Therapy News, founded Cell Therapy Blog, founded and continues to manage the LinkedIn Cell Therapy Industry Group, co-founded Regenerative Medicine Jobs, and is an active industry commentator in publications and in social media. Mr. Buckler serves on numerous industry conference advisory boards, is an advisory board member for BioCision, Phacilitate Cell & Gene Therapy and RoosterBio, and is on the Board of Directors for Hemostemix.
To learn more about Lee Buckler and Replicel, log on to www.Replicel.com.
